Publication | Open Access
TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target
19
Citations
20
References
2023
Year
TROP-2 protein expression is of prognostic value in HPV-independent VSCC. The broad expression of TROP-2 in VSCC indicates the TROP-2 directed ADC Sacituzumab govitecan as a potential new therapeutic strategy for VSCC patients.
| Year | Citations | |
|---|---|---|
Page 1
Page 1